Tag Archive for: health outcomes

The task force represents diverse stakeholders from across the clinical research ecosystem, including representatives from academic medical centers and universities, biotechnology and pharmaceutical companies, AI technology researchers, and IRB ethicists, members, and chairs.

Researchers from Analysis Group have coauthored the first large-scale study that revealed racial disparities in treatment, survival, and access to care among patients with metastatic castration-sensitive prostate cancer (mCSPC) since the first novel hormonal therapy was approved in 2018.

In 2024, the pharmaceutical industry finds itself confronting high complexity and competition — embracing innovative strategies to navigate these challenges is paramount to ensuring commercial success.

The world has never been so diverse, and it is even more evident when you look at the upcoming Cannes Lions 2024.

This strategic acquisition combines BioCentric’s medical affairs and commercial expertise with JPA Health’s integrated services, predictive analytics and AI-driven solutions.

Collecting patient data through electronic PROs (ePROs) or electronic clinical outcome assessments (eCOAs) has been integral for patient centricity. These tools allow sponsors to meet patients where they are to gather real-time insights directly from the source, boosting patient retention and engagement. ePROs and eCOAs improve clinical trial outcomes with additional data points around a patient’s experience. However, the addition of consumer technologies that can collect ambient data points is poised to enhance outcomes even more, bringing treatments faster to those who need them most.

While it’s never actually possible to fully predict the future, we are looking ahead to how artificial intelligence and other emerging technologies – combined with the human touch of professionals – will shape the future of the business of healthcare and pharmaceuticals for generations to come. Before looking at AI’s potential impacts in the space, we must first take stock of the macro trends in healthcare.

The collaboration will include the development of computational pathology algorithms powered by AI and machine learning (ML) that connect baseline pathology data, such as molecular tumor profiles, with clinical data, such as patient outcomes, to enable better patient identification, stratification, and selection for clinical trials.

Artificial intelligence (AI) surely stands at the forefront of one of the most transformative periods in the pharmaceutical industry. Its rapid drug discovery capabilities and potential for personalized patient care mark AI as a revolutionary influence in reshaping the pharmaceutical industry. Central to this transformation is natural language processing (NLP).

Fitbit and Quest Diagnostics have announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences the risk of developing several diseases, including diabetes and heart disease.